Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

251.17 -17.96 (-6.67%)
Streaming Delayed Price Updated: 12:08 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?
Based on a technical and fundamental analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
From Insulet Corporation
Via Business Wire
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Reasons Investors Love Insulet (PODD)
Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was partly due to its solid quarterly results, and... 
Via StockStory
Topics Stocks
Exposures US Equities
What's Driving the Market Sentiment Around Insulet?
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today
Via Benzinga
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
From Insulet Corporation
Via Business Wire
Insulet Announces Pricing of Senior Notes Due 2033
From Insulet Corporation
Via Business Wire
Assessing Insulet: Insights From 6 Financial Analysts
Via Benzinga
Insulet Announces Proposed Financing Transactions
From Insulet Corporation
Via Business Wire
Insulet Expands Omnipod® 5 to Four More International Markets
From Insulet Corporation
Via Business Wire
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
From Insulet Corporation
Via Business Wire
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Insulet to Host Investor Day on June 5, 2025
From Insulet Corporation
Via Business Wire
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Exploring the Growth Potential of INSULET CORP (NASDAQ:PODD) as It Nears a Breakout.
Based on fundamental and technical analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD): a strong growth stock preparing for the next leg up?. 
Via Chartmill
1 Mid-Cap Stock on Our Watchlist and 2 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Which S&P500 stocks are moving on Tuesday?
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends. 
Via Chartmill
Earnings To Watch: Masimo (MASI) Reports Q4 Results Tomorrow
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Integra LifeSciences (IART) Reports Earnings Tomorrow: What To Expect
Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Curious about which S&P500 stocks are generating unusual volume on Friday? Find out below.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth. 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session
Curious about the S&P500 stocks that are showing activity before the opening bell on Friday? 
Via Chartmill
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next... 
Via StockStory
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.